At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Recurrent Respiratory Papillomatosis. Completed, enrolled 21 participants across 2 sites.
Detailed Summary
This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs. The investigators will be using Pembrolizumab as the treating agent.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Respiratory Papillomatosis
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartApr 2016
Primary CompletionFeb 2022
Study CompletionDec 2025
TodayJul 2026
First PostedDec 16, 2015
Enrollment StartApr 1, 2016
Primary CompletionFeb 1, 2022
Study CompletionDec 1, 2025
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 10.5 years ago
Interventions
Pembrolizumabdrug
200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.